Myriad Genetics Stock Forecast, Price & News

Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions

Is Myriad Genetics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Myriad Genetics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares.
View analyst ratings for Myriad Genetics or view top-rated stocks.

How has Myriad Genetics' stock been impacted by COVID-19?

Myriad Genetics' stock was trading at $14.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MYGN shares have increased by 82.0% and is now trading at $25.53.
View which stocks have been most impacted by COVID-19.

When is Myriad Genetics' next earnings date?

Myriad Genetics is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Myriad Genetics.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) released its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.02). The company had revenue of $167.30 million for the quarter, compared to analyst estimates of $164.35 million. Myriad Genetics had a negative trailing twelve-month return on equity of 3.71% and a negative net margin of 9.32%. During the same quarter last year, the company posted ($0.19) EPS.
View Myriad Genetics' earnings history.

What price target have analysts set for MYGN?

3 Wall Street analysts have issued 12 month target prices for Myriad Genetics' shares. Their forecasts range from $25.00 to $35.00. On average, they anticipate Myriad Genetics' share price to reach $30.00 in the next year. This suggests a possible upside of 17.5% from the stock's current price.
View analysts' price targets for Myriad Genetics or view top-rated stocks among Wall Street analysts.

Who are Myriad Genetics' key executives?

Myriad Genetics' management team includes the following people:

• Paul J. Diaz, President, Chief Executive Officer & Director
• R. Bryan Riggsbee, Chief Financial Officer, Treasurer & Executive VP
• Jerry S. Lanchbury, Chief Scientific Officer
• Kevin R. Haas, Chief Technology Officer
• Thomas P. Slavin, Chief Medical Officer

What is Paul Diaz's approval rating as Myriad Genetics' CEO?

12 employees have rated Myriad Genetics CEO Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among Myriad Genetics' employees.

Who are some of Myriad Genetics' key competitors?

Some companies that are related to Myriad Genetics include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Incyte (INCY), Exact Sciences (EXAS), Novavax (NVAX), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of MYGN's competitors.

What other stocks do shareholders of Myriad Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (17.37%), Wellington Management Group LLP (4.05%), Camber Capital Management LP (3.44%), Dimensional Fund Advisors LP (3.36%), Glenview Capital Management LLC (2.80%) and Goldman Sachs Group Inc. (2.73%). Company insiders that own Myriad Genetics stock include Alexander Ford, Daniel K Spiegelman, Dennis Langer, Jayne B Hart, Jerry S Lanchbury, Jerry S Lanchbury, Nicole Lambert, Paul Parkinson, Richard Bryan Riggsbee, S Louise Phanstiel and Walter Phd Gilbert.
View institutional ownership trends for Myriad Genetics.

Which major investors are selling Myriad Genetics stock?

MYGN stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Camber Capital Management LP, Glenview Capital Management LLC, Millennium Management LLC, Point72 Asset Management L.P., Goldman Sachs Group Inc., Dimensional Fund Advisors LP, and Citigroup Inc.. Company insiders that have sold Myriad Genetics company stock in the last year include Daniel K Spiegelman, Dennis Langer, Jayne B Hart, Jerry S Lanchbury, Nicole Lambert, Paul Parkinson, Richard Bryan Riggsbee, and S Louise Phanstiel.
View insider buying and selling activity for Myriad Genetics or view top insider-selling stocks.

Which major investors are buying Myriad Genetics stock?

MYGN stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Polar Asset Management Partners Inc., Artisan Partners Limited Partnership, CastleArk Alternatives LLC, Nordea Investment Management AB, Balyasny Asset Management LLC, Balyasny Asset Management LLC, and Renaissance Technologies LLC. Company insiders that have bought Myriad Genetics stock in the last two years include S Louise Phanstiel, and Walter Phd Gilbert.
View insider buying and selling activity for Myriad Genetics or or view top insider-buying stocks.

How do I buy shares of Myriad Genetics?

Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $25.53.

How much money does Myriad Genetics make?

Myriad Genetics has a market capitalization of $2.04 billion and generates $638.60 million in revenue each year. The company earns $-44.20 million in net income (profit) each year or ($0.87) on an earnings per share basis.

How many employees does Myriad Genetics have?

Myriad Genetics employs 2,700 workers across the globe.

Does Myriad Genetics have any subsidiaries?

The following companies are subsidiares of Myriad Genetics: AssureRx Canada Ltd, Assurex Health Inc., Crescendo Bioscience Inc, Javelin Pharmaceuticals, MVZ Fur Molekulardiagnostik GmbH, Myriad Autoimmune, Myriad Genetic Laboratories Inc., Myriad Genetics Australia PTY LTD, Myriad Genetics B.V., Myriad Genetics Canada Corp, Myriad Genetics Espana SL, Myriad Genetics GmbH, Myriad Genetics LTD, Myriad Genetics S.r.l., Myriad Genetics SAS, Myriad GmbH, Myriad International GmbH, Myriad Neuroscience, Myriad RBM Inc., Myriad Services GmbH, Myriad Women’s Health, NaturNorth Technologies, Privatklinik Dr. Robert Schindlbeck, Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG, Rules-Based Medicine, and Sividon Diagnostics.

When was Myriad Genetics founded?

Myriad Genetics was founded in 1991.

What is Myriad Genetics' official website?

The official website for Myriad Genetics is www.myriad.com.

Where are Myriad Genetics' headquarters?

Myriad Genetics is headquartered at 320 WAKARA WAY, SALT LAKE CITY UT, 84108.

How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at (801) 584-3600, via email at [email protected], or via fax at 801-584-3640.